News Sol-Gel Technologies Ltd. Deutsche Boerse AG

Equities

4SG

IL0011417206

Market Closed - Deutsche Boerse AG Other stock markets 02:00:35 2024-06-28 EDT			5-day change	1st Jan Change
0.765 ^EUR	-5.56%		-5.56%	-29.17%

05-28	Sol-Gel Technologies Gets Noncompliance Notice From Nasdaq	MT
05-28	Sol-Gel Technologies Ltd. Announces Resignation of Gilad Mamlok as Chief Financial Officer, Effective September 21, 2024	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sol-Gel Technologies Gets Noncompliance Notice From Nasdaq	05-28	MT
Sol-Gel Technologies Ltd. Announces Resignation of Gilad Mamlok as Chief Financial Officer, Effective September 21, 2024	05-28	CI
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice	05-28	AQ
HC Wainwright Adjusts Sol-Gel Technologies Price Target to $6 From $9, Maintains Buy Rating	05-20	MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20	CI
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates	05-20	AQ
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel	05-16	AQ
Sol-Gel Technologies Ltd. and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize Twyneo® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel	05-16	CI
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream	04-01	AQ
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments	03-13	AQ
Sol-Gel Technologies Ltd. Elects Yuval Yanai as External Director	02-29	CI
Transcript : Sol-Gel Technologies Ltd. - Special Call	12-06
Sol-Gel Technologies Ltd. Screens First Patient for SGT-610 Phase 3 Study	11-30	CI
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study	11-30	AQ
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610	11-28	AQ
Sol Gel Technologies : INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K - Form 6-K	11-20	PU
Sol-Gel Technologies Ltd. Announces Resignation of Shmuel Ben Zvi from Board	11-20	CI
HC Wainwright Cuts Sol-Gel Technologies' Price Target to $9 From $12, Keeps Buy Rating	11-13	MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sol-Gel Technologies Ltd. Deutsche Boerse AG

Equities

4SG

IL0011417206

Summary

Filters